Immunotransplant

Repertoire Immune Medicines Presents First Clinical Data on PRIME IL-15 Cell Therapy in Advanced Metastatic Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Monday, November 9, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Clinical medicine, Medicine, Medical specialties, Immunology, Lymphocytes, Oncology, Cancer treatments, Virotherapy, Immunotransplant, Tumor-infiltrating lymphocytes, PRIME IL-15, Repertoire Immune Medicines

Following administration of PRIME IL-15, 10 of 17 patients with advanced metastatic disease had stable disease, of which four and patients were stable for more than six months.

Key Points: 
  • Following administration of PRIME IL-15, 10 of 17 patients with advanced metastatic disease had stable disease, of which four and patients were stable for more than six months.
  • Clinical biomarker data also provided evidence of PRIME IL-15 biological activity.
  • The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.
  • To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter .

Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program

Retrieved on: 
Friday, May 29, 2020
Health, Medicine, Lymphocytes, Oncology, Tumor-infiltrating lymphocytes, Melanoma, Therapy, Iovance Biotherapeutics, Immunotransplant, Adoptive cell transfer

We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program, said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics.

Key Points: 
  • We are very pleased to present the long term follow up data for lifileucel in melanoma at the ASCO Scientific Program, said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics.
  • The median duration of response has not been reached at 18.7 months of study follow up supporting potential benefit of the one-time treatment of lifileucel TIL therapy in advanced melanoma patients.
  • Updated interim results from Cohort 2 are now available from an oral abstract session titled, Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
  • A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.

COVID-19 Stem Cell Therapies Pipeline Insight 2020, Featuring 22 Stem Cell Therapy Companies in APAC, EMEA and the Americas

Retrieved on: 
Monday, May 11, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Stem cell research, Stem-cell therapy, Cell therapy, Therapy, Immunotransplant, New York Stem Cell Foundation

DUBLIN, May 11, 2020 /PRNewswire/ -- The "COVID-19 Stem Cell Therapies Pipeline" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 11, 2020 /PRNewswire/ -- The "COVID-19 Stem Cell Therapies Pipeline" report has been added to ResearchAndMarkets.com's offering.
  • Complementing the slew of vaccines in development are the upcoming stem cell therapies, aimed at boosting patients' immune systems and eliminating pathogens.
  • The COVID-19 Stem Cell Therapies Pipeline report provides comprehensive data analysis of 22 organizations developing stem cell therapies for COVID-19 globally from the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific region (APAC).
  • The report covers stem cell therapy market with detailed review of their cell therapy research and development including the stages of production (pre-clinical, clinical and commercial).

COVID-19 Stem Cell Therapies Pipeline, 2020 Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 7, 2020
Infectious diseases, Health, Stem cells, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Stem cell research, Stem-cell therapy, Cell therapy, Therapy, Immunotransplant, New York Stem Cell Foundation

The "COVID-19 Stem Cell Therapies Pipeline" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Stem Cell Therapies Pipeline" report has been added to ResearchAndMarkets.com's offering.
  • Complementing the slew of vaccines in development are the upcoming stem cell therapies, aimed at boosting patients' immune systems and eliminating pathogens.
  • The COVID-19 Stem Cell Therapies Pipeline report provides comprehensive data analysis of 22 organizations developing stem cell therapies for COVID-19 globally from the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific region (APAC).
  • The report covers stem cell therapy market with detailed review of their cell therapy research and development including the stages of production (pre-clinical, clinical and commercial).